Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
9.15
-0.10 (-1.08%)
At close: Nov 4, 2025, 4:00 PM EST
9.00
-0.15 (-1.64%)
After-hours: Nov 4, 2025, 4:23 PM EST
Elicio Therapeutics Employees
Elicio Therapeutics had 32 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
32
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,706,625
Market Cap
149.36M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32 | 0 | - |
| Dec 31, 2023 | 32 | 9 | 39.13% |
| Dec 31, 2022 | 23 | -1 | -4.17% |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELTX News
- 1 day ago - Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting - GlobeNewsWire
- 8 days ago - Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial - GlobeNewsWire
- 5 weeks ago - Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 6 weeks ago - Elicio Therapeutics Reports Inducement Grants - GlobeNewsWire
- 6 weeks ago - Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis - GlobeNewsWire